| Dual roles of PARP-1 promote cancer growth and progression MJ Schiewer, JF Goodwin, S Han, JC Brenner, MA Augello, JL Dean, ... Cancer discovery 2 (12), 1134-1149, 2012 | 486 | 2012 |
| A hormone–DNA repair circuit governs the response to genotoxic insult JF Goodwin, MJ Schiewer, JL Dean, RS Schrecengost, R de Leeuw, ... Cancer discovery 3 (11), 1254-1271, 2013 | 408 | 2013 |
| Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019 VN Giri, KE Knudsen, WK Kelly, HH Cheng, KA Cooney, MS Cookson, ... Journal of Clinical Oncology 38 (24), 2798-2811, 2020 | 271 | 2020 |
| Transcriptional roles of PARP1 in cancer MJ Schiewer, KE Knudsen Molecular cancer research 12 (8), 1069-1080, 2014 | 206 | 2014 |
| Targeting the p300/CBP axis in lethal prostate cancer J Welti, A Sharp, N Brooks, W Yuan, C McNair, SN Chand, A Pal, ... Cancer Discovery 11 (5), 1118-1137, 2021 | 192 | 2021 |
| DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis JF Goodwin, V Kothari, JM Drake, S Zhao, E Dylgjeri, JL Dean, ... Cancer cell 28 (1), 97-113, 2015 | 187 | 2015 |
| A patient‐derived explant (PDE) model of hormone‐dependent cancer MM Centenera, TE Hickey, S Jindal, NK Ryan, P Ravindranathan, ... Molecular oncology 12 (9), 1608-1622, 2018 | 131 | 2018 |
| USP22 regulates oncogenic signaling pathways to drive lethal cancer progression RS Schrecengost, JL Dean, JF Goodwin, MJ Schiewer, MW Urban, ... Cancer research 74 (1), 272-286, 2014 | 128 | 2014 |
| Novel actions of next-generation taxanes benefit advanced stages of prostate cancer R de Leeuw, LD Berman-Booty, MJ Schiewer, SJ Ciment, RB Den, ... Clinical Cancer Research 21 (4), 795-807, 2015 | 121 | 2015 |
| MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer R De Leeuw, C McNair, MJ Schiewer, NP Neupane, LJ Brand, ... Clinical Cancer Research 24 (17), 4201-4214, 2018 | 120 | 2018 |
| Targeting cell cycle and hormone receptor pathways in cancer CES Comstock, MA Augello, JF Goodwin, R De Leeuw, MJ Schiewer, ... Oncogene 32 (48), 5481-5491, 2013 | 117 | 2013 |
| The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair AA Shafi, CM McNair, JJ McCann, M Alshalalfa, A Shostak, TM Severson, ... Nature communications 12 (1), 401, 2021 | 96 | 2021 |
| Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells C Paolillo, Z Mu, G Rossi, MJ Schiewer, T Nguyen, L Austin, ... Clinical Cancer Research 23 (20), 6086-6093, 2017 | 86 | 2017 |
| Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene NA Olshavsky, CES Comstock, MJ Schiewer, MA Augello, T Hyslop, ... Cancer Research 70 (10), 3975-3984, 2010 | 79 | 2010 |
| Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors SN Chand, M Zarei, MJ Schiewer, AR Kamath, C Romeo, S Lal, ... Cancer research 77 (18), 5011-5025, 2017 | 77 | 2017 |
| PARP inhibitors in prostate cancer P Ramakrishnan Geethakumari, MJ Schiewer, KE Knudsen, WK Kelly Current treatment options in oncology 18, 1-16, 2017 | 74 | 2017 |
| The AR dependent cell cycle: mechanisms and cancer relevance MJ Schiewer, MA Augello, KE Knudsen Molecular and cellular endocrinology 352 (1-2), 34-45, 2012 | 72 | 2012 |
| PARP‐1 regulates DNA repair factor availability MJ Schiewer, AC Mandigo, N Gordon, F Huang, S Gaur, R de Leeuw, ... EMBO molecular medicine 10 (12), e8816, 2018 | 70 | 2018 |
| Linking DNA damage and hormone signaling pathways in cancer MJ Schiewer, KE Knudsen Trends in Endocrinology & Metabolism 27 (4), 216-225, 2016 | 68 | 2016 |
| Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer JD Steffen, RM Tholey, MF Langelier, JL Planck, MJ Schiewer, S Lal, ... Cancer research 74 (1), 31-37, 2014 | 66 | 2014 |
